From pharmacogenomics to improved patient outcomes: Angiotensin I-converting enzyme as an example

Diabetes Technology and Therapeutics

Volumn 4, Issue 4, 2002, Pages 519-532

  Moskowitz, David W ^a  

^a GenoMed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; QUINAPRIL; RAMIPRIL;

AGED; ALLERGY; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CAUCASIAN; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE ACTIVITY; GENE DELETION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HUMAN; HYPERKALEMIA; HYPERTENSION; LUNG EMPHYSEMA; MALE; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOMICS; GENOTYPE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MISSOURI; PEPTIDYL-DIPEPTIDASE A; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 0036382632     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091502760306616     Document Type: Review

References (38)

1. Collins FS: Shattuck Lecture-medical and societal consequences of the Human Genome Project. N Engl J Med 1999;341:28-37.
2. Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R: Design and base-line characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996;17(Suppl 4):3S-16S.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 145-153.
4. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
5. Moskowitz DW: The human gene pool: limits to human health. In: von Pfusterschmid-Hardenstein H, ed. Das normale und das pathologische-was ist gesund? Europaisches Forum Alpbach 1996. Vienna: Ibera Verlag, 1997:50-70, 680-681.
6. Gohda T, Makita Y, Shike T, Kobayashi M, Funabiki K, Haneda M, Kikkawa R, Watanabe T, Baba T, Yoshida H, Tomino Y: Association of the DD geno-type and development of Japanese type 2 diabetic nephropathy. Clin Nephrol 2001;56:475-480.
7. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F: Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993;290 (Pt 1):33-40.
8. Bruneval P, Hinglais N, Alhenc-Gelas F, Tricottet V, Corvol P, Menard J, Camilleri JP, Bariety J: Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization. Histochemistry 1986;85:73-80.
9. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-E8.
10. Blais C Jr, Marceau F, Rouleau JL, Adam A: The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 2000; 21:1903-1940.
11. Lehninger AL: Biochemistry. New York: Worth Publishers, 1970:153.
12. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A: Plasma bradykinin in angiooedema. Lancet 1998;351:1693-1697.
13. Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R: The safety and tolerability of quinapril. J Cardiovasc Pharmacol 1990;15(Suppl 2):S47-S55.
14. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL Jr: Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol. 2000;86:519-523.
15. Dzau VJ: Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-1052.
16. Johnston CI, Fabris B, Yamada H, Mendelsohn FA, Cubela R, Sivell D, Jackson B: Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989;7(5):S11-S16.
17. Kaplan HR, Taylor DG, Olson SC, Andrews LK: Quinapril - a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology 1989;40 (4 Pt 2):335-350.
18. Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation 1988;77(6 Pt 2):174-178.
19. Lyons D, Webster J, Benjamin N: Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51(5):373-378.
20. Wei L, Clauser E, Alhenc-Gelas F, Corvol P: The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992;267:13398-13405.
21. Zabka J, Stribrna J, Rotnaglova Z: Response of peripheral plasma renin activity (PRA) to furosemide stimulation; reduction of the renal parenchyma as a limiting factor. Physiol Bohemoslov 1981;30(5): 397-403.
22. Moskowitz DW, Liu W: Gene expression after uninephrectomy in the rat: simultaneous expression of positive and negative growth control elements. J Urol 1995;154:1560-1565.
23. Moskowitz DW, Gillespie KN, Sutera SP, Druce HM, Merli CA, Simon EE: Evidence for acute renal cortical vasoconstriction after uninephrectomy. Ren Fail 1996;18:833-846.
24. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249(3 Pt 2):F324-F337.
25. Bonnet F, Cao Z, Cooper ME: Apoptosis and angiotensin II: yet another renal regulatory system? Exp Nephrol 2001;9:295-300.
26. Hamet P, deBlois D: Endothelial and myocyte apoptosis-role of angiotensin II. Can J Cardiol 2001;17 (Suppl A):26A-28A.
27. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992;268:3085-3091.
28. Liao Y, Husain A. The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995;11(Suppl F):13F-19F.
29. Saggar-Malik AK, Afzal AR, Swissman JS, Bland M, Sagnella GA, Eastwood JB, MacGregor GA, Jeffery S: Lack of association of ACE/angiotensinogen geno-type with renal function in autosomal dominant polycystic kidney disease. Genet Test 2000;4:299-303.
30. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-999.
31. Palatini P: Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of anti-hypertensive drugs. Drugs 1999;57:713-724.
32. Loscalzo J, Creager MA, Dzau VJ: Vascular Medicine: A Textbook of Vascular Biology and Diseases, 2nd edit. Boston: Little, Brown and Co., 1996:160.
33. Schmieder FA, Comerota AJ: Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001;87 (12A):3D-13D.
34. Costerousse O, Allegrini J, Clozel JP, Menard J, Alhenc-Gelas F: Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther 1998;284: 1180-1187.
35. Mitch WE, Walser M, Buffington GA, Lemann J Jr: A simple method of estimating progression of chronic renal failure. Lancet 1976;2:1326-1328.
36. Papp M, Li X, Zhuang J, Wang R, Uhal BD: Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 2002;282:L713-L718.
37. Burke AP, Farb A, Pestaner J, Malcom GT, Zieske A, Kutys R, Smialek J, Virmani R: Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. Circulation 2002;105:419-424.
38. Rieder MJ, Taylor SL, Clark AG, Nickerson DA: Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999;22:59-62.